Beyond cytotoxic chemotherapy for the first-line treatment of HER2-negative, hormone-insensitive metastatic breast cancer: Current status and future opportunities

Clinical Breast Cancer

Volumn 8, Issue 3, 2008, Pages 215-223

  Conlin, Alison K ^a   Seidman, Andrew D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Ixabepilone; Microvessel density; Sunitinib

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; IRINOTECAN; IXABEPILONE; LONIDAMINE; METHOTREXATE; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PROGESTERONE RECEPTOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; VINBLASTINE;

ANGIOGENESIS; ASTHENIA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CHILL; CORRELATION ANALYSIS; DRUG INTERMITTENT THERAPY; DRUG TARGETING; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HAND FOOT SYNDROME; HEART DISEASE; HORMONE RESISTANCE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; ONCOGENE NEU; PAIN; RASH; REVIEW; SIGNAL TRANSDUCTION; VOMITING;

EID: 46949104444     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2008.n.024     Document Type: Review

References (74)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006; 56:168-83.
3. Carrick S, Parker S, Wilcken N, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005; 2(CD003372).
4. Sledge GW, Neuberg D, Bernardo P, et al. Phase III trial of doxorubicin, paclitaxel and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003; 21:588-92.
5. Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998; 16:3720-30.
6. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17:1413-24.
7. Bishop J, Dewar J, Toner G, et al. Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer. J Clin Oncol 1999; 17:2355-64.
8. Heidemann E, Stoeger H, Souchon R, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial. Ann Oncol 2002; 13:1717-29.
9. Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18:2385-94.
10. Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous vinorelbine in combination with epirubicin verus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 22:2313-20.
11. Berruti A, Bitossi R, Gorzegno G, et al. Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase II study with a factorial design. J Clin Oncol 2002; 20:4150-9.
12. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812-23.
13. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. Proc Am Soc Clin Oncol 2004; 22(suppl):14S (Abstract 510).
14. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74.
15. Jones S, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542-51.
16. Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and ramdom assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B Protocol 9840. J Clin Oncol 2008; 26:1642-49.
17. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polythylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-803.
18. Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210-17.
19. Dombernowsky P, Gehl J, Boesgaard M, et al. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 1996; 23(5 suppl):23-7.
20. Misset JL, Dieras V Gruia G, et al. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer. Ann Oncol 1999; 10:553-60.
21. Viens P, Roche H, Kerbrat P, et al. Epirubicin-docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study. Am J Clin Oncol 2001; 24:328-35.
22. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005; 11:5678-85.
23. Carey LA, Dees EC, Sawyer LR, et al. The triple negative paradox: Primary tumor chemosensitivity of the breast cancer subtypes. Clin Cancer Res 2007; 13:2329-34.
24. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7.
25. Rugo HS, Thomas ES, Lee RK, et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes. Breast Cancer Res Treat 2007; 106(suppl 1):S270 (Abstract 6069).
26. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characteristics of the basal-liek subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10:5367-74.
27. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406:747-52.
28. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
29. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203:661-71.
30. Livasy CA, Karaca G, Nanda R, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19:264-71.
31. Abd El-Rehim DM, Ball G, Pinder SE, et al. High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005; 116:340-50.
32. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a populationbased study. Proc Natl Acad Sci U S A 2003; 100:10393-8.
33. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418-23.
34. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrencee. Clin Cancer Res 2007; 13:4429-34.
35. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer study. JAMA 2006; 295:2492-502.
36. ClinicalTrials.gov [Web site]. Cetuximab Alone and Cetuximab with Carboplatin in ER/PR-Negative, HER-2 Nonoverexpressing Metastatic Breast Cancer. Available at: http://www.clinicaltriais.gov/ ct/show/NCT00232505?order=l. Accessed: June 6, 2008.
37. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevaeizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-99.
38. Miller KD, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Eng J Med 2007; 357:2666-76.
39. Ramaswamy B, Elias AD, Kelbick NT, et al. Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clin Cancer Res 2006; 12:3124-9.
40. Perez EA, Hillman DW, Kugler JW, et al. North Central cancer treatment group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 2006; 100(suppl):S104 (Abstract 2069).
41. Link JS, Waisman JR, Jacobs CI. Bevaeizumab and albumin bound paclitaxel treatment in metastatic breast cancer. Breast Cancer Res Treat 2006; 100(suppl 1):S69 (Abstract 1095).
42. Miller KD, Burstein HJ, Elias AD, et al. Phase II study of SU 11248, a multi-targeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol 2005; 23:19s (Abstract 563).
43. Bianchi G, Loibl S, Zamagni C, et al. A phase II multicentre uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer. Eur J Can 2005; 3:78 (Abstract 276).
44. Modi S, D'Andrea G, Norton L, et al. A phase I study of cetuximab/ paclitaxel in patients with advanced-stage breast cancer. Clin Breast Cancer 2006; 7:270-7.
45. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-over-expressing metastatic breast cancer. J Clin Oncol 2002; 20:719-26.
46. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48.
47. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23:2162-71.
48. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783-92.
49. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23:4265-74.
50. Seidman AD, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-21.
51. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82:4-6.
52. Cobleigh MA, Langmuir VK, Sledge GW, et al. A phase I/II dose escalation trial of bevaeizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30(5 suppl):117-24.
53. Miller K, Gradishar W, Moisa C, et al. Capecitabine plus bevaeizumab in first line metastatic breast cancer: an interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. Breast Cancer Res Treat 2006; 100(suppl 1):S103 (Abstract 2068).
54. ClinicalTrials.gov [Web site]. A Study Evaluating the Efficacy and Safety of Bevaeizumab in Combination with Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1). Available at: http:// www.clinicaltrials.gov/ct/show/ NCT00262067?order= 1. Accessed: June 6, 2008.
55. ClinicalTrials.gov [Web site]. A Study to Evaluate the Safety and Efficacy of Bevaeizumab in Combination with Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2). Available at: http://www.clinicaltrials. gov/ct/show/NCT00281697?order = l. Accessed: June 6, 2008.
56. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevaeizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 2005; 23:7135-42.
57. Moreno-Aspitia A, Hillman DW, Wiesenfeld M, et al. BAY 43-9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane. J Clin Oncol 2006; 24(18 suppl):22s (Abstract 577).
58. Silverman P, Lyons J, Fu P, et al. Randomized phase II study of docetaxel ± bevaeizumab for locally advanced unresectable breast cancer: impact on biomarkers of angiogenesis. Breast Cancer Res Treat 2006; 100(suppl 1):S242 (Abstract 5086).
59. Tang J, Zhao J, Pan L, et al. Effects of systemic chemotherapy on circulating angiogenic factor levels in patients with breast cancer. Breast Cancer Res Treat 2006; 100:S243
60. Rugo HS, Dickler MN, Traina TA, et al. Change in circulating endothelial cells (CEC predicts progression free survival (PFS) in patients (pts) with hormone receptor positive metastatic breast cancer (MBC) receiving letrozole (L) and bevaeizumab (B). J Clin Oncol 2006; 24(18 suppl):130s (Abstract 3039).
61. Schneider BR Radovich M, Sledge GW, et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 2007 [Epub ahead of print].
62. Schneider BR Wang M, Radovich M, et al. Association of genetic polymorphisms of VEGF and VEGFR-2 with outcome in E2100. Breast Cancer Res Treat 2007; 106(suppl 1):S78 (Abstract 1107).
63. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84:1875-87.
64. Linderholm B, Grankvist K, Wilking N, et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18:1423-31.
65. Linderholm B, Tavelin B, Grankvist K, et al. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol 1998; 16:3121-8.
66. Uzzan B, Nicolas P, Cucherat M, et al. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 2004; 64:2941-55.
67. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol 2006; 24:769-77.
68. Siziopikou KP, Ariga R, Proussaloglou KE, et al. The challenging ER-negative/PR-negative/HER2-negative patient; a promising candidate for EGFR targeted therapy? Breast Cancer Res Treat 2006; 12:360-2.
69. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109:25-32.
70. Doane AS, Danso M, Lal P, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25:3994-4008.
71. Doane AS, Moynahan ME, Zhang L, et al. PIK3CA mutation is frequent in class A estrogen receptor-negative breast cancer and contributes to the distinct molecular profile. Breast Cancer Res Treat 2006; 100:S293.
72. ClinicalTrials.gov [Web site]. Combined Treatment of Cetuximab and Paclitaxel in Basal Like Breast Carcinoma. Available at: http://www. clinicaltrials.gov/ct/show/NCT00353717?order=5. Accessed: June 6, 2008.
73. O'Shaughnessy J, Weckstein DJ, Vukelja SJ, et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106(suppl l):s206 (Abstract 308).
74. Morgensztern D, McLeod HL. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 2005; 16:797-803.